Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Focus On Asia

Set Alert for Focus on Asia

Two Chinese IPOs Kickstart A Hectic Biotech Fundraising Season

Two IPOs and 12 venture capital and private equity deals in China raised a combined $1bn in a hectic few weeks of October.

China Financing

Biocon Buoyant On ‘Unique Positioning’ Of Partnered COVID-19 Antibody

Biocon management signals the potential of its partnered entry with Serum Institute and Adagio Therapeutics into the communicable diseases segment. Continuing large supply opportunities for COVID-19 vaccines and prospects for boosters, alongside the promising profile of the neutralizing antibody being developed by its US-based partner, also bode well.

Commercial Coronavirus COVID-19

Scorching COVID-19 Era Returns From India Biotech, Healthcare Funds Outpace The Globe

Early COVID-19 therapies including Gilead’s remdesivir, China-plus procurement policies, vaccine partnerships and a dovish stance by the central bank led to returns on India biotech and healthcare funds outperforming global returns. Meanwhile, funding for e-pharmacies and online consulting firms gathered pace.

Commercial Financing

China Hits Two Billion COVID Jabs But More Effective mRNA Shots Elude

Despite administering a total of 2.2 billion COVID-19 shots, China as the first country to experience the coronavirus outbreak has yet to open its borders, while more effective mRNA vaccines are still nowhere to be found amid apparent delays for the licensed-in lead candidate.

China Coronavirus COVID-19

High Stakes: Boehringer Faces Pre-Expiry India Jardiance Challenge

Indian firms debut empagliflozin copies ahead of expected patent expiry for diabetes blockbuster Jardiance in the country. Spotlight now on how swiftly Boehringer Ingelheim can fend off the entrants and whether the local challenge goes well beyond “inspiration” from the goings-on in the case of another SGLT2 inhibitor dapagliflozin.

Commercial Intellectual Property

Emerging Biopharma’s Next First Launch Market: China?

Despite multiple challenges including pricing pressures and slowing general economic growth, China offers attractive opportunities for emerging biopharma firms, helped by an encouraging regulatory environment. But weighing up options around challenging areas including partnering is essential, a new report states. 

China Commercial

ADC Competition Heats Up In China But Caution, Pressure Also Mount

After the anti-PD-1/L1 antibody and cell therapy rush, antibody-drug conjugates are quickly gaining attention in China as new technologies and deal-making activity heats up, but one first mover warns of potential over-crowding.

China Deals

CEO Pay Packages Expand in India But Ratio To Employee Earnings Hurts

Top executives at leading local and foreign drug firms in India by and large earned more in 2020-21, while differentials in CEO to median employee remuneration remained stark. With increasing scrutiny by shareholders and lawmakers, experts suggest that pharma should be more mindful of balancing “adequate” C-suite compensation and glaring inequalities.

India Leadership

EyeGene: EG-COVID Will Be Starting Point For Other mRNA Vaccines

EyeGene R&D head talks to Scrip at CPhI Korea about the development of its COVID-19 vaccine candidate EG-COVID, potential challenges in clinical trials and positioning and the over-riding importance of validating a viable mRNA platform.

South Korea Coronavirus COVID-19

Shanghai Kick-Starts New Consortium To Develop First-In-Class Cancer Drugs

A concerted effort to mobilize the pharma industry, research organizations and state-backed healthcare venture capital firms is under way in Shanghai.

China Financing

BeiGene/BMS Parting Abraxane Ways As China Supply Woes Continue

The latest development over the licensing arrangement for the anticancer drug may deal a further blow to BeiGene’s oncology commercial efforts in China.

China Commercial

EuBiologics On COVID-19 Vaccine And Fulfilling Public Health Mission

EuBiologics CEO Yeong Ok Baik sat down with Scrip at CPhI Korea to talk about why he wants to develop vaccines for global public health needs and what plans are in store for its late-stage recombinant protein candidate for COVID-19.

South Korea Coronavirus COVID-19
See All
UsernamePublicRestriction

Register